Warren Buffett's huge losses on Teva mount

Warren Buffett Photo: ASAP Creative

Berkshire Hathaway has kept its 4% stake in the Israeli pharmaceutical company, costing it hundreds of millions of dollars 'on paper.'

Berkshire Hathaway reported last night that it has maintained its holding of 43.2 million shares and 4% stake in Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA). However, the news that investment guru Warren Buffett, the chairman, CEO and largest shareholder in Berkshire Hathaway has kept his position in Teva did not boost the company's share price. On a bearish NYSE, Teva fell 10.51% to $6.30, giving a market cap of $7.167 billion as Moody's lowered its outlook for the Israeli pharmaceutical company from stable to negative and Congress members accused it of obstructing a price-fixing probe.

Thus Berkshire Hathaway's 4% stake in Teva is now worth just $272 million. Berkshire Hathaway was not required to report how much it paid for its position in the Israeli pharmaceutical company. However, taking the average price in the period that the position was built up - late 2017 and early 2018 - Berkshire Hathaway likely paid $756 million for its shares. So on paper, Berkshire Hathaway is sustaining losses of more than $480 million.

Published by Globes, Israel business news - en.globes.co.il - on August 15, 2019

© Copyright of Globes Publisher Itonut (1983) Ltd. 2019

Warren Buffett Photo: ASAP Creative
Warren Buffett Photo: ASAP Creative
Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018